Ena Respiratory Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Accelerator/Inc
- Latest Deal Amount
-
$2.98M
- Investors
-
14
Ena Respiratory General Information
Description
Developer of immunomodulators designed to prevent respiratory viral infections. The company's products allow for topical delivery to the airways in order to target the primary site and activate the innate immune system in the respiratory tract to prevent viral and bacterial dissemination to the lungs, enabling patients with pre-existing lung disease to stay safe from further critical complications.
Contact Information
Website
www.enarespiratory.comCorporate Office
- Level 9 31 Queen Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- Level 9 31 Queen Street
- Melbourne, Victoria 3000
- Australia
Ena Respiratory Timeline
Ena Respiratory Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 01-Jan-2026 | $2.98M | Completed | Clinical Trials - General | ||
| 6. Later Stage VC (Series B) | 22-Oct-2025 | Completed | Clinical Trials - General | |||
| 5. Later Stage VC | 27-Jan-2025 | Completed | Clinical Trials - General | |||
| 4. Grant | 09-Jan-2023 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 15-Jun-2021 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC (Series A) | 01-Sep-2020 | $8.43M | $13.2M | Completed | Clinical Trials - General | |
| 1. Seed Round | 01-May-2017 | $4.75M | $4.75M | Completed | Clinical Trials - General |
Ena Respiratory Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Ena Respiratory Patents
Ena Respiratory Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021902855-A0 | Formulation | Inactive | 02-Sep-2021 | ||
| AU-2022338350-A1 | Formulation | Pending | 02-Sep-2021 | ||
| CA-3226951-A1 | Formulation | Pending | 02-Sep-2021 | ||
| EP-4395762-A1 | Formulation | Pending | 02-Sep-2021 | ||
| EP-4395762-A4 | Formulation | Pending | 02-Sep-2021 | A61K47/60 |
Ena Respiratory Signals
Ena Respiratory Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Biointelect | Accelerator/Incubator | |||
| Gates Foundation | Not-For-Profit Venture Capital | Minority | ||
| Flu lab | Impact Investing | Minority | ||
| United States Department of War | Government | |||
| AustralianSuper | Limited Partner | Minority |
Ena Respiratory FAQs
-
When was Ena Respiratory founded?
Ena Respiratory was founded in 2014.
-
Where is Ena Respiratory headquartered?
Ena Respiratory is headquartered in Melbourne, Australia.
-
What is the size of Ena Respiratory?
Ena Respiratory has 9 total employees.
-
What industry is Ena Respiratory in?
Ena Respiratory’s primary industry is Drug Discovery.
-
Is Ena Respiratory a private or public company?
Ena Respiratory is a Private company.
-
What is Ena Respiratory’s current revenue?
The current revenue for Ena Respiratory is .
-
How much funding has Ena Respiratory raised over time?
Ena Respiratory has raised $71.1M.
-
Who are Ena Respiratory’s investors?
Biointelect, Gates Foundation, Flu lab, United States Department of War, and AustralianSuper are 5 of 14 investors who have invested in Ena Respiratory.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process